Clinical

Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.

John Kitchens, MD, explores how GLP-1s, novel drug pipelines, and Medicaid access gaps are shaping the future of DME management.

Brittany G. Craiglow, MD, FAAD, discusses the psychiatric and psychosocial toll of alopecia in children and adolescents, and its impact on treatment initiation.

FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

People with HIV born after 1980 had an 81% lower risk of hepatitis B coinfection than earlier cohorts, highlighting the lasting impact of childhood vaccination.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

In this episode, 'Bridging the Gap Between ACR Guidelines and Real-World RA Management,' the expert rheumatologist explored the following questions: • The American College of Rheumatology (ACR) guidelines provide a framework for rheumatoid arthritis (RA) management, but there's often a gap between what guidelines recommend and what happens in practice for RA. Where do you see the biggest disconnect, and what's driving it?

This segment explores emerging challenges in treatment sequencing for hormone receptor–positive, HER2-negative metastatic breast cancer as oral selective estrogen receptor degraders move into earlier lines of therapy.

Noureddin acknowledged the extraordinary challenge facing primary care physicians who are tasked with managing a patient holistically across rapidly evolving fields and expressed genuine appreciation for the breadth of responsibility they carry.

Body surface area offers a simple starting point for gauging vitiligo severity, but the panel argues that phenotype markers, anatomic location, and disease activity carry more weight in shaping treatment urgency than surface area alone.

In this episode titled, 'Practical Disease Activity Scoring for Rheumatoid Arthritis Follow-Up Visits', Dr. Julia Buchfuhrer led the conversation about the following questions: • Let's start with how you're assessing disease activity in RA patients in routine practice. Which scoring tools are you using most consistently, and how are you building reassessment into the care cycle? • How frequently are you bringing patients back to formally reevaluate disease activity after a treatment change and what is your clinical rationale for this decision?

This segment explores the evolving role of oral selective estrogen receptor degraders in early-stage hormone receptor–positive, HER2-negative breast cancer and their potential impact on treatment paradigms.

Noureddin outlined the striking epidemiological burden of MASLD and MASH in patients with obesity, with prevalence climbing dramatically with increasing BMI, reaching up to 90% in patients with a BMI of 40 or higher, and affecting approximately 60% of individuals with type 2 diabetes.

Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a patient needs urgent intervention or watchful monitoring.

In this episode, 'Traditional Pharmacologic Therapies for Alzheimer's Disease Agitation: Mechanisms, Evidence, and Adverse Events,' the expert neurologists explored the following questions: What are the traditional therapies such as antipsychotics used in the management of patients with Alzheimer's disease agitation and their respective mechanisms of action? What has the data demonstrated with these therapies? What are the adverse events seen with these therapies? When are you utilizing dose reductions with these therapies?

In 'Non-Pharmacologic Approaches to Alzheimer's Disease Agitation: Interventions, Best Practices, and Case Examples,' the expert neurologists examined the following critical questions: Before we get into the medications used to treat Alzheimer's disease agitation, what are the non-pharmacologic options and their respective roles? What are best practices for educating patients and caregivers on these and some case examples?

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Led by the moderator, Christina Poh shared her closing reflections on the relapsed or refractory follicular lymphoma treatment landscape, expressing strong optimism about both the current state and near-term future of the field, noting that the development of many novel, highly effective treatment options over the past several years has fundamentally transformed what is possible for patients with this chronic, relapsing disease.

Christina Poh described the real-world data from eight CUBIC centers as highly encouraging, interpreting response rates that match or exceed those seen in pivotal trials in a heavily pretreated and older patient population as confirmation that bispecific antibodies are a broadly active and impressive class of treatment that already plays an important role in relapsed or refractory follicular lymphoma.